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Background: Bronchial thermoplasty (BT) is a new therapeutic option for severe refractory asthma not controlled
despite high dose inhaled corticosteroids plus long-acting bronchodilators and omalizumab in selected cases. Risk
of pulmonary atelectasis after BT in severe asthma has been described in literature, but no details have been reported
on the possible mechanisms of the complication.
Case presentation: A 49-year-old male with severe uncontrolled asthma was referred to BT. One hour after the first
procedure, acute respiratory failure occurred with PaO2/FiO2 < 300. A CT scan showed atelectasis of the right lower and
middle lobes. A new bronchoscopy was performed under non-invasive ventilation; the right lower and middle lobe
bronchus were occluded by bronchus-shaped plugs, that were very difficult to remove despite repeated saline
washings and fragmentation with forceps. The patient had a rapid resolution of respiratory failure. Four weeks later,
6 hours after the second session of BT, severe bronchospasm occurred with respiratory failure. Chest X-Ray showed
atelectasis of the left lower lobe, prompting to perform a new flexible bronchoscopy on non-invasive ventilation.
The exam showed again a plug occluding the left lower lobar bronchus, removed with forceps and washings. The
histological analysis of the plugs demonstrated the massive presence of fibrin with mucus debris, rare Charcot-Leyden
crystals, scattered macrophages, neutrophils, eosinophils and bronchial epithelial cells.
Conclusion: The originality of our case report is related to the recurrence of bronchial plugging with lobar
atelectasis within one and five hours respectively, after two sequential BT procedures. At the histological
evaluation the bronchial plugs appeared very different from the typical mucoid asthma plugs, being composed
prevalently by fibrin. It can be hypothesized that intense thermal stimulation of the bronchial mucosa may
represent a strong boost for inflammation in susceptible patients, with microvascular alteration induced directly
by heat or through the release of mediators.
Although in severe asthma a risk of atelectasis from the classical asthma mucoid plugs may be expected, the peculiarity
of our case resides in the formation of fibrin plugs whose direct correlation with BT should be considered.
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Figure 1 Atelectasis of the right lower and middle lobe.
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Bronchial thermoplasty (BT) is a new therapeutic option
for severe refractory asthma not controlled, despite high
dose inhaled corticosteroids plus long-acting bronchodi-
lators and omalizumab in selected cases. BT represents a
really new treatment paradigm from regular daily high
dose medications to a long-term and potentially permanent
control of smooth muscle-induced bronchospasm [1]. The
procedure is designed to target airways smooth muscle,
which contributes to bronchocostriction in asthma [2].
During BT, radiofrequency energy is applied to provide
thermal treatment (65°C) of visible airways > 3 mm in
diameter. A special catheter, introduced via a flexible bron-
choscope, is used to apply the treatment in three sessions
with 3–4 week intervals. Three international randomized
clinical trials in patients with asthma demonstrated the
safety of this technique with an acceptable rate of post-
treatment adverse events in the short-term and a significant
improvement in the rate of asthma exacerbations [3-5].
Recently, results of 5-year-follow up were published
with evidence of persistent AQLQ (asthma quality of life
questionnaire) improvement, reduction in exacerbations,
hospitalisation and emergency room accesses; good out-
comes about long-term safety profile of BT were also
reported [6].
The aim of this article is to report an unusual case of
acute complication due to recurrent atelectasis of lower
lung lobes occurring after each of 2 sequential proce-
dures of bronchial thermoplasty.
Case presentation
A 49-year-old male had severe bronchial asthma accord-
ing to ATS/ERS definition [1]. Although the broncho-
dilator reversibility test was positive (FEV1 + 14% versus
a baseline of 66% predicted), a fixed obstruction was
present in stable conditions. He was a non-smoker pa-
tient, with prior nasal polypectomy, and he had common
variable immunodeficiency as comorbidity. Normal ANCA
levels excluded a Churg-Strauss syndrome. Asthma con-
trol was very poor (ACT score 18) with a very low quality
of life (AQLQ 3.3) despite high dose inhaled therapy
(budesonide 800 mcg/die, formoterol 24 mcg/die and as
needed, tiotropium 18 mcg/die), and oral prednisone 8 mg
daily. The use of anti-IgE monoclonal antibodies was not
allowed, because serum IgE levels were above the upper
safety limit for indication. The patient was referred to BT
and enrolled in an experimental clinical BT-ASMN trial
(ClinicalTrials.gov Identifier: NCT01839591) [7]. Standard
procedures of premedication were applied, with prednis-
one 50 mg as required by protocol for three days, i.e. the
day before, the same day, and the day after the procedure.
The first session of BT was performed on spontaneous
breathing in deep sedation with remifentanil 0,10 mcg/
Kg/h and propofol 8 mg/Kg/h administered underanesthesiology assistance. Copious mucus secretions and
hyperemic bronchial mucosa were found at bronchos-
copy examination. Fifty valid activations were adminis-
tered in the bronchi of the right lower lobe without
complications, such as O2 desaturation or bleeding.
After one hour, acute respiratory failure occurred with
PaO2/FiO2 < 300. On physical examination, there was a
reduction of breath sounds in the right lower lobe, se-
vere bronchospasm elsewhere with tachypnea. A CT
scan showed atelectasis of the right lower and middle
lobes (Figure 1). A new bronchoscopy was performed on
non-invasive ventilation with face mask (Esprit ventilator
Philips-Respironics inc. PVC/AC mode; Performax face
mask Philips-Respironics inc.) through Respironics
swivel connector to ensure adequate gas exchange. Right
lower and middle lobe bronchi were almost completely
occluded by bronchus-shaped plugs (Figure 2). The re-
moval of the plugs was very hard despite repeated washings
with physiological saline and mechanical fragmentation
with forceps (Figure 3). The patient had a rapid resolution
of respiratory failure with progressive improvement of gas
exchange, and was discharged after twelve days.
Four weeks later, a second session of BT was per-
formed after the same premedication and deep sedation
protocols. Sixty-one valid activations were administered
in the bronchi of the left lower lobe. Bronchoscopy
showed reduction in secretions as compared to the first
session. Six hours later, a severe bronchospasm occurred
with respiratory failure. Chest X-Ray showed a partial
atelectasis of the left lower lobe. A flexible bronchoscopy
on non-invasive ventilation showed again a plug occlud-
ing the left lower lobar bronchus. The plug was removed
with forceps fragmentation and washings. After five days
the patient was discharged.
The histological analysis of the plugs demonstrated a
massive presence of fibrin with mucus debris, rare
Charcot-Leyden crystals, scattered macrophages, neutro-
phils, eosinophils and bronchial epithelial cells (Figure 4).
Figure 2 Plugs blocking the right lower and middle lobar
bronchus.
Figure 4 At histologic examination, the plug consisted mainly of
fibrin mixed with some mucus, scattered inflammatory cells, and
some small aggregates of bronchial cells. Haematoxylin-Eosin, 40X.
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The third session of BT was performed after one
month. Eighty two valid activations were administered in
the bronchi of the two upper lobes, without any
complications.
The clinical and functional evaluation performed
12 months after the end of BT showed a good control of
asthma without any kind of exacerbations. The FEV1
value is increased from 66% at baseline to 75% after
12 months, AQLQ score from 3.3 to 5.8 and ACT score
decreased from 18 to 6.
Discussion
Published trials have shown that BT is a safe procedure
with a low incidence of adverse events, usually corre-
lated to airways irritation [3]. The most common event
is represented by exacerbation of asthma (52% versus
39% of the control group), which mainly occurs in the
24 hours after the procedure but resolves in most cases
within one week. To minimize the risk of an exacerba-
tion, patients areusually treated with oral steroids forFigure 3 Bronchus-shaped plug.three days, before , the day before, and the day after the
procedure. In the RISA trial [4] Pavord I. et al. described
two cases of segmental atelectasis secondary to treat-
ment with BT, including one treated with bronchoscopy
and another one with chest physiotherapy. In the AIR 2
[5] study, three segmental atelectasis were reported in
two patients, but treatment modalities and characteris-
tics of plugs were not described in detail. As compared
to literature, the originality of our report is related to the
recurrence of lobar atelectasis complication in the same
patient within one and five hours respectively, after two
sequential BT procedures. In addition, we report details
on the histological evaluation of the mucus plugs which
appear different from the typical bronchial asthma plugs.
Plugging of small and medium-sized airways by mucus
and cellular debris is a well known feature of fatal
asthma found in autopsy studies in both adults and chil-
dren. The biochemical composition of the typical asthma
plugs include plasma proteins, DNA, and proteoglycans,
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Mucins have notably different cross-linking, size, acidity
and appearance (assessed by electron microscopy) com-
pared with control mucus. Cellularity in the plugs is
mainly represented by scattered eosinophils and some
epithelial cells [8-11].
Helper T-cell type 2 (Th2) cytokines, including inter-
leukin (IL)-13, are implicated in mucus production and
goblet cell hyperplasia in asthma and IL-13 induces gob-
let cell hyperplasia with mucus hypersecretion in human
airway epithelial cells [12]. Despite our patient presented
with diffuse bronchial hypersecretion at the first endo-
scopic evaluation, as typically found in severe asthma,
the composition of the post-BT plug was atypical, preva-
lently derived from blood serum components. It is well
known that plasma exudation from the bronchial micro-
vasculature and tissue oedema are characteristic features
of asthma [13]. Vascular leakage of plasma results from
inflammatory mediator-induced separation of endothelial
cells in the postcapillary venules of the tracheobronchial
circulation, with increase in macromolecular permeability.
Plasma exudate in the airway lumen in asthma may
contribute to sloughing of epithelium, impairment of
mucociliary transport, narrowing of small airways, and
mucus plug formation [14].
It can be hypothesized that intense thermal stimula-
tion of the bronchial mucosa may represent a strong
boost for inflammation, in susceptible patients, with
microvascular alteration induced directly by heat or
through the release of mediators causing mucosal exud-
ation, oedema and formation of plugs rich in fibrin com-
position, as in our case. There is no explanation at the
moment on the occurrence of such a mechanism only in
some asthma patients and not in others. A further
anomaly was represented by the fact that in the same
patient the third BT procedure applied to the upper
lobes did not cause atelectasis; there are no data to ex-
plain such a discrepancy between lower and upper lobes,
e.g. in terms of different anatomy or physiology or fac-
tors directly related to BT.
Conclusions
In literature, the number of patients treated with BT is
still small to draw any definitive conclusion. It will be
necessary to foster a close surveillance and reporting of
adverse events correlated with BT in order to better
understand how this method impacts with the anatomy
and physiology of the bronchial mucosa.
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